Baird Medical Showcases Cutting-Edge MWA Innovations at NASOIE 2025

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD), a medical device company specializing in AI-powered surgical robotics and microwave ablation (MWA) technology, showcased its innovations at the 2025 North American Society of Interventional Endocrinologists (NASOIE) Annual Meeting in Lehi, Utah.

The company's booth attracted significant physician interest, featuring hands-on thyroid phantom demonstrations that highlighted their MWA technology's precision, safety, and efficiency. Company experts engaged with attendees in detailed discussions about clinical applications and practical insights regarding MWA in thyroid care.

The event, which focuses on advancing minimally invasive treatments for thyroid and parathyroid disorders, provided Baird Medical an opportunity to reinforce its position in next-generation thyroid ablation therapies. The company plans to utilize insights gained from NASOIE 2025 to further enhance its MWA technology for thyroid treatment solutions.

Positive

• Strong physician engagement at industry conference
• Successful demonstration of MWA technology capabilities
• Reinforced market position in thyroid ablation therapies

Negative

• None.

NEW YORK, March 3, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a forward-thinking medical device company specializing in AI-powered surgical robotics and next-generation surgical instruments, and a global leader in microwave ablation (MWA) technology, made a lasting impact at the 2025 North American Society of Interventional Endocrinologists (NASOIE) Annual Meeting in Lehi, Utah.

As a premier gathering for experts in interventional endocrinology, NASOIE serves as a platform for advancing minimally invasive treatments for thyroid and parathyroid disorders. The event convenes top-tier clinicians and researchers to explore the latest breakthroughs in treating thyroid nodules and cancer recurrences.

Baird Medical's presence at NASOIE 2025 drew strong engagement, with numerous physicians visiting the booth to explore the latest advancements in MWA technology. Attendees participated in hands-on thyroid phantom demonstrations, experiencing firsthand the precision, safety, and efficiency of Baird's technology. The Company's experts engaged in in-depth discussions, addressing key clinical considerations and providing practical insights into MWA's role in thyroid care. Through these interactions, Baird Medical further solidified its leadership in next-generation thyroid ablation therapies, enhancing industry awareness, and reinforcing its commitment to innovation in minimally invasive treatment solutions.

Baird Medical remains dedicated to advancing minimally invasive thyroid treatments by working closely with medical experts and industry leaders. The insights gained from NASOIE 2025 will help further refine the Company's MWA technology, ensuring it meets the evolving needs of thyroid care. Through continued research, education, and collaboration, Baird Medical is committed to improving treatment options for patients with thyroid nodules and related conditions worldwide.

About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave ablation (MWA) technology, offering advanced treatment solutions for conditions such as thyroid nodules, breast disease, uterine fibroids, and liver cancer. A publicly traded company on NASDAQ, Baird Medical is dedicated to enhancing patient care through precision, efficiency, and safety in its innovative medical devices. For more information, please visit https://bairdmed.com/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and generally relate to future events or Baird Medical's future financial or operational performance. In some cases, you can identify forward-looking statements by terminology such as "may," "might," "will," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue," or the negative of these terms or other similar expressions.

These forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results or outcomes to differ materially from those expressed or implied. These statements are based on estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. Risks and uncertainties may emerge over time, and it is not possible to anticipate all potential factors that could affect Baird Medical's business and financial performance.

Factors that could cause actual results to differ materially include, but are not limited to: (1) the risk that Baird Medical may not achieve its expansion goals in the United States, China, or other markets; (2) changes in economic, regulatory, or market conditions that impact Baird Medical's operations; (3) the ability to realize anticipated benefits from ongoing business initiatives or strategic transactions; (4) regulatory developments and compliance with applicable laws; (5) risks related to the development, commercialization, and market acceptance of Baird Medical's products; and (6) other risks and uncertainties detailed in Baird Medical's filings with the SEC.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Baird Medical undertakes no obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-showcases-cutting-edge-mwa-innovations-at-nasoie-2025-302389649.html

SOURCE BDMD

FAQ

What did Baird Medical (BDMD) showcase at NASOIE 2025?

Baird Medical showcased its microwave ablation (MWA) technology through hands-on thyroid phantom demonstrations, highlighting the precision, safety, and efficiency of their thyroid treatment solutions.

How did physicians respond to Baird Medical's (BDMD) presentation at NASOIE 2025?

Physicians showed strong engagement, with numerous attendees visiting the booth to explore MWA technology advancements and participate in hands-on demonstrations.

What is the significance of NASOIE 2025 for Baird Medical (BDMD)?

NASOIE 2025 allowed Baird Medical to strengthen its leadership in thyroid ablation therapies, enhance industry awareness, and gather insights for future technology refinements.

How will Baird Medical (BDMD) utilize the feedback from NASOIE 2025?

The company will use insights from NASOIE 2025 to refine their MWA technology and improve treatment options for patients with thyroid nodules and related conditions.